StockData

Apollomics vs Immunome

APLM and IMNM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How APLM and IMNM compare

Immunome scores higher on the StockData Score (7 against 0 for Apollomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAPLMIMNM
Size and price
Market cap–$2.0B
Share price$16.84$17.18
Change, 1 year−31.4%0.23%
Change, 5 years−98.3%1.2%
Beta (5Y)0.171.62
Employees14177
StockData Score
Total score07 (better)
Valuation score00
Growth score00
Performance score01 (better)
Health score06 (better)
Dividend score00
Valuation
P/S–486×
P/B–3.3×
FCF yield–−10.5%
Growth
Revenue growth (TTM)–−63.3%
Profitability
Operating margin–−5948%
Net margin–−5594%
FCF margin–−5119%
Return on equity–−50.1%
Financial health
Debt / equity–0.00
Current ratio0.9621.68 (better)
Altman Z-score–35.70
Piotroski F-score–4
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–104%
Held by insiders76.0%6.4%
Insider net buying, 12 months$8.3M (better)−$25.2M
Short interest, % of float–15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.